N-(3-bromo-5-fluorophenyl)acetamide | 807620-95-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-bromo-5-fluorophenyl)acetamide
• CAS: 807620-95-7
• 化学式: C₈H₇BrFNO
• 分子量: 232.052
• InChiKey: MJLNEORGKPLPCW-UHFFFAOYSA-N

物化性质

• 沸点：
  333.1±32.0 °C(Predicted)
• 密度：
  1.623±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-bromo-5-fluorophenyl)acetamide 在 盐酸 、 sodium hydroxide 、 四(三苯基膦)钯 、 Pd(dppf) 、 potassium acetate 、 potassium carbonate 、 sodium nitrite 作用下， 以 乙二醇二甲醚 、 乙醇 、 二甲基亚砜 为溶剂， 反应 2.0h， 生成 2-[2-(3-fluoro-5-pyridin-4-ylphenyl)-2H-tetrazol-5-yl]pyridine
  参考文献：
  名称：

  3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist

  摘要：

  Structure-activity relationship studies performed around 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile for the purpose of developing novel mGlu5 receptor antagonists are described. Synthesis of a series of four-ring tetrazoles led to the discovery of 3-[3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine, a highly potent, brain penetrant, azole-based mGlu5 receptor antagonist. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.011
• 作为产物：
  描述：

  1-溴-3-氟-5-硝基苯 在 铁粉 、 氯化铵 、 三乙胺 作用下， 以 乙醇 、 水 、 乙酸乙酯 为溶剂， 反应 6.0h， 生成 N-(3-bromo-5-fluorophenyl)acetamide
  参考文献：
  名称：

  [EN] EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF
  [FR] INHIBITEUR DE L'EGFR ET COMPOSITION ET UTILISATION DE CELUI-CI
  [ZH] EGFR抑制剂及其组合物和用途

  摘要：

  提供了式A化合物，使用这些化合物作为EGFR抑制剂的方法，以及包含这些化合物的药物组合物。该化合物可用于治疗、预防或改善诸如癌症或感染的疾病或病症。

  公开号：

  WO2022206797A1

文献信息

• [EN] SUBSTITUTED TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS
  申请人：LUPIN LTD

  公开号：WO2021105960A1

  公开（公告）日：2021-06-03

  Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, Formula (I) wherein, ring A, R1 to R5, X, Y, m, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

  揭示了通式（I）的化合物，其互变异构体，其立体异构体，其药用可接受盐，其多晶形式，或其溶剂合物，通式（I）中，环A，R1至R5，X，Y，m和n如本文所定义，用作治疗增殖性、传染性和RAS病或紊乱的SOS1抑制剂。还揭示了合成通式I化合物的方法，含有通式I化合物的药物组合物，治疗增殖性、传染性和RAS病或紊乱的方法，例如，通过给予所述化合物和通式I化合物与其他活性成分的组合物。
• [EN] INHIBITORS OF JUN N-TERMINAL KINASE<br/>[FR] INHIBITEURS DE L'ENZYME JUN N-TERMINAL KINASE
  申请人：ELAN PHARM INC

  公开号：WO2010091310A1

  公开（公告）日：2010-08-12

  The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula (I): or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.

  本公开提供了具有以下结构的c-Jun N-末端激酶（JNK）抑制剂（I）的结构，或其盐或溶剂化物，其中环A，Ca，Cb，Z，R5，W和Cy在此处定义。本公开还提供了包括本公开化合物的药物组合物，以及制备和使用本公开化合物和组合物的方法，例如在治疗和预防各种疾病，如阿尔茨海默病。
• 3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: Identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists
  作者：Lida R. Tehrani、Nicholas D. Smith、Dehua Huang、Steve F. Poon、Jeffrey R. Roppe、Thomas Jon Seiders、Deborah F. Chapman、Janice Chung、Merryl Cramer、Nicholas D.P. Cosford

  DOI：10.1016/j.bmcl.2005.07.062

  日期：2005.11

  3-position led to a substantial increase in in vitro potency. In particular, 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile (7) is a highly potent and selective mGlu5 receptor antagonist with good rat pharmacokinetics, brain penetration, and in vivo receptor occupancy.

  对3-（5-吡啶-2--2-基-2H-四唑-2-基）苄腈2的苯环的构效关系研究导致发现在3-位的小的非氢键供体取代基大大提高了体外效能。特别是3-氟-5-（5-吡啶-2-基-2H-四唑-2-基）苄腈（7）是一种高效且选择性的mGlu5受体拮抗剂，具有良好的大鼠药代动力学，脑渗透性和体内活性受体占用。
• Concise syntheses of GB22, GB13, and himgaline by cross-coupling and complete reduction
  作者：Eleanor M. Landwehr、Meghan A. Baker、Takuya Oguma、Hannah E. Burdge、Takahiro Kawajiri、Ryan A. Shenvi

  DOI：10.1126/science.abn8343

  日期：2022.3.18

  Neuroactive metabolites from the bark of Galbulimima belgraveana occur in variable distributions among trees and are not easily accessible through chemical synthesis because of elaborate bond networks and dense stereochemistry. Previous syntheses of complex congeners such as himgaline have relied on iterative, stepwise installation of multiple methine stereocenters. We decreased the synthetic burden of himgaline chemical space to nearly one-third of the prior best (7 to 9 versus 19 to 31 steps) by cross-coupling high fraction aromatic building blocks (high F _sp 2) followed by complete, stereoselective reduction to high fraction sp ³ products (high F _sp 3). This short entry into Galbulimima alkaloid space should facilitate extensive chemical exploration and biological interrogation.

  < p >自< italic > Galbulimima belgraveana < /italic >树皮中的神经活性代谢产物在树木之间的分布变化很大，由于复杂的键网络和密集的立体化学结构，通过化学合成难以获得。以前合成复杂同分异构体如himgaline的方法依赖于多个甲烷立体中心的迭代、逐步安装。我们通过交叉偶联高分数芳香基本块（高F _{sp < /sub> 2）然后完全、立体选择性地还原为高分数sp ^{3 < /sup> 产物（高F sp < /sub> 3），将himgaline化学空间的合成负担减少到先前最佳的三分之一左右（从19到31步减少到7到9步）。这种进入< italic > Galbulimima < /italic >生物碱空间的简短方法应该有助于进行广泛的化学探索和生物学研究。< /p>}}
• Compounds for the treatment of multi-drug resistant bacterial infections
  申请人：AstraZeneca AB

  公开号：US07875715B2

  公开（公告）日：2011-01-25

  The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

  本发明涉及表现出抗菌活性的化合物，其制备过程，含有其作为活性成分的药物组合物，以及它们作为药物的使用和用于制造用于治疗温血动物（如人类）细菌感染的药物的使用。特别地，本发明涉及用于治疗温血动物（如人类）细菌感染的有用化合物，更具体地涉及这些化合物用于制造用于治疗温血动物（如人类）细菌感染的药物。